Related Experiment Video

Updated: Jul 14, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Targeting the PI3K-Akt pathway in kidney cancer

Jin-Young Park1, Pei-yin Lin, Robert H Weiss

  • 1Division of Nephrology, Department of Internal Medicine, Immunology Graduate Group, University of California, Davis, CA 95616, USA. jyppark@ucdavis.edu

Expert Review of Anticancer Therapy
|June 9, 2007
PubMed

Insights

Kidney cancer that has spread has a poor outlook. Researchers are exploring new therapies targeting the PI3K-Akt pathway, but toxicity remains a challenge for current inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Kidney cancer (renal cell carcinoma) is rare but often metastatic at diagnosis, leading to poor prognoses.
  • Conventional chemotherapy is largely ineffective for advanced kidney cancer.
  • The PI3K-Akt signaling pathway is crucial for cell survival and growth, making it a potential therapeutic target.

Purpose of the Study:

  • To review the status of PI3K-Akt inhibitors and related pathway modulators for kidney cancer treatment.
  • To discuss the challenges and promise of targeting the PI3K-Akt cascade in renal cell carcinoma.

Main Methods:

  • Literature review of PI3K-Akt inhibitors and associated signaling pathways.
  • Analysis of preclinical and clinical data for targeted therapies in kidney cancer.

Main Results:

  • While the PI3K-Akt pathway is a theoretically ideal target, current inhibitors face toxicity issues, limiting clinical application.
  • Inhibitors of upstream and downstream components of the PI3K-Akt cascade show promise.

Conclusions:

  • Targeting the PI3K-Akt pathway remains a significant area of research for kidney cancer.
  • Further development is needed to overcome toxicity and optimize therapeutic strategies for renal cell carcinoma.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...